IGRELIMOGENE LITADENOREPVEC
UNII 484TEV85XS

Substance Identification & Data

This profile provides standardized clinical and technical data for Igrelimogene Litadenorepvec, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 484TEV85XS.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2646695-70-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

484TEV85XS

CAS Registry Number

2646695-70-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

IGRELIMOGENE LITADENOREPVEC

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C175454

National Cancer Institute reference terminology for clinical and research data.

INN ID

12394

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Igrelimogene Litadenorepvec. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

IGRELIMOGENE LITADENOREPVEC

Common Names & Synonyms

DNA (RECOMBINANT TUMOR-SELECTIVE REPLICATING ONCOLYTIC ADENOVIRUS 5 VECTOR TILT-123 E2F PROMOTER PLUS HUMAN TUMOR NECROSIS FACTOR-.ALPHA. FUSION WITH INTERNAL RIBOSOME ENTRY SITE ELEMENT FUSION WITH HUMAN INTERLEUKIN 2 PLUS HUMAN ADENOVIRUS 3 FIBER KNOB PROTEIN-SPECIFYING)

IGRELIMOGENE LITADENOREPVEC [INN]

IGRELIMOGENE LITADENOREPVEC [WHO-DD]

RECOMBINANT, REPLICATION-COMPETENT ONCOLYTIC ADENOVIRUS TYPE 5 (AD5) VECTOR ENCODING HUMAN TUMOUR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.) AND HUMAN INTERLEUKIN 2 (IL-2) SEPARATED BY AN INTERNAL RIBOSOMAL ENTRY SITE (IRES), INSERTED INTO THE E3 REGION DELETED FOR GP19K/6.7K, AND UNDER CONTROL OF THE VIRAL E3 PROMOTER. VIRAL REPLICATION IS UNDER CONTROL OF A TUMOUR-SELECTIVE E2F PROMOTER THAT IS LINKED TO A 24-BP DELETION IN THE ADENOVIRAL E1A REGION. THE GENE ENCODING THE VIRAL FIBER PROTEIN IS A CHIMERA WITH AN ADENOVIRUS (AD) TYPE 3 KNOB SEQUENCE AND AN AD TYPE 5 SHAFT AND TAIL SEQUENCE

External Clinical & Regulatory Resources

Previous UNII484S40W57K

Next UNII484WSW570C